BioCity Biopharmaceutics Announces Clinical Collaboration to Evaluate BC3195 + KEYTRUDA combination in Patients with Locally Advanced or Metastatic Solid Tumors March 18, 2025
SOTIO Expands ADC Pipeline and Synaffix Collaboration to Develop Two Novel Bispecific Candidates, SOT112 and SOT113 March 18, 2025
ImmunoPrecise Antibodies and a Global Biotechnology Company Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics March 18, 2025
Head and Neck Cancer Registration Study Protocol Clears FDA Review; in Talks with Potential Partners Interested in Commercialization of Multikine March 18, 2025
Pierre Fabre Laboratories and RedRidge Bio Announce Drug Discovery and Co-development Partnership March 12, 2025
Molecular Partners – Novartis collaboration to develop DARPin-conjugated radioligands for cancer comes to an end March 11, 2025
Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen March 11, 2025
IDEAYA Biosciences and ATTMOS to use AI/ML-Enabled Drug Discovery for Oncology Targets March 11, 2025
Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline March 4, 2025
Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell Engagers March 4, 2025
Swarm Oncology Ltd. and Cellex Cell Professionals GmbH Announce Strategic Partnership to Advance Swarm’s Innovative T Cell Therapies for Solid Cancers March 4, 2025
Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 March 4, 2025
Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate February 25, 2025
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage February 25, 2025
Epitopea Announces License and Research Collaboration Agreement with MSD to Identify CryptigenTM Tumor-Specific Antigens February 25, 2025
Arcus Biosciences Retains Rights to Casdatifan and Announces Pricing of $150 Million Common Stock Offering February 25, 2025
Myris Therapeutics Developing Ultra-High DAR ADCs to Enable Novel Precision Medicine Treatments for Cancer February 25, 2025
